NCT06636435
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 1, 2020
Completion: Jun 30, 2026